Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Inc (APGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,810,536
  • Shares Outstanding, K 45,027
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,990 K
  • EBIT $ -178 M
  • EBITDA $ -181 M
  • 60-Month Beta 2.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.42

Options Overview Details

View History
  • Implied Volatility 58.33% ( -2.64%)
  • Historical Volatility 79.12%
  • IV Percentile 3%
  • IV Rank 7.85%
  • IV High 89.74% on 10/15/24
  • IV Low 55.65% on 05/23/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 255
  • Volume Avg (30-Day) 191
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 2,180
  • Open Int (30-Day) 1,630

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.94
  • Number of Estimates 4
  • High Estimate -0.84
  • Low Estimate -0.98
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -193.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.48 +10.22%
on 01/16/25
50.56 -20.47%
on 01/07/25
-7.29 (-15.35%)
since 12/23/24
3-Month
36.48 +10.22%
on 01/16/25
63.50 -36.68%
on 11/11/24
-11.22 (-21.82%)
since 10/23/24
52-Week
32.78 +22.67%
on 02/02/24
72.29 -44.38%
on 03/13/24
+5.46 (+15.71%)
since 01/23/24

Most Recent Stories

More News
Insider Purchase: Director at $APGE (APGE) Buys 12,500 Shares

Mark C. McKenna, a director at $APGE ($APGE), bought 12,500 shares of the company on 12-12-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

APGE : 40.21 (+3.31%)
Apogee Therapeutics Advances Phase 1 Clinical Trial for APG333 in Asthma and COPD with Interim Data Expected in 2H 2025

Apogee Therapeutics initiates Phase 1 trial for APG333 targeting respiratory diseases, with interim data expected in 2025.Quiver AI SummaryApogee Therapeutics has initiated a Phase 1 clinical trial for...

APGE : 40.21 (+3.31%)
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

APGE : 40.21 (+3.31%)
Insider Sale: Chief Medical Officer of $APGE (APGE) Sells 6,665 Shares

Carl Dambkowski, the Chief Medical Officer of $APGE ($APGE), sold 6,665 shares of the company on 12-04-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.5%...

APGE : 40.21 (+3.31%)
Apogee Therapeutics Reports Positive Phase 1 and 2 Data for APG808 and APG777, Highlighting Potential for Innovative Dosing Regimens in Inflammatory and Immunology Markets

Apogee Therapeutics announced positive Phase 1 data for APG808 and APG777, highlighting potential for prolonged dosing in inflammatory diseases.Quiver AI SummaryApogee Therapeutics reported positive interim...

APGE : 40.21 (+3.31%)
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

APGE : 40.21 (+3.31%)
Apogee Therapeutics Announces R&D Day Agenda Focusing on Innovative Treatment Opportunities in Inflammatory and Immunology Conditions

Apogee Therapeutics announces virtual R&D Day agenda focusing on novel biologics for inflammatory and immunology conditions.Quiver AI SummaryApogee Therapeutics, Inc. has announced its agenda for a virtual...

APGE : 40.21 (+3.31%)
Apogee Therapeutics Announces Agenda for Virtual R&D Day

APGE : 40.21 (+3.31%)
Apogee Therapeutics Announces Virtual R&D Day Focused on Advancements in Inflammatory and Immunology Treatments

Apogee Therapeutics will host a virtual R&D Day on December 2, 2024, discussing its innovative programs and strategies.Quiver AI SummaryApogee Therapeutics, Inc., a clinical-stage biotechnology company...

APGE : 40.21 (+3.31%)
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

APGE : 40.21 (+3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Apogee Therapeutics LLC is a biotechnology company advancing novel, potentially therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee Therapeutics LLC is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 44.59
2nd Resistance Point 42.67
1st Resistance Point 41.44
Last Price 40.21
1st Support Level 38.29
2nd Support Level 36.37
3rd Support Level 35.14

See More

52-Week High 72.29
Fibonacci 61.8% 57.20
Fibonacci 50% 52.53
Fibonacci 38.2% 47.87
Last Price 40.21
52-Week Low 32.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar